Oligodendroglioma, IDH-mutant and 1p/19q-codeleted: lines of therapy
4 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Risk group | Grade 2, high risk, and grade 3 | Radiotherapy followed by PCV (procarbazine, lomustine, vincristine), the regimen validated in RTOG 9402, EORTC 26951 and RTOG 9802; radiotherapy with temozolomide is an alternative being compared in CODEL. | NCCN Guidelines: Central Nervous System Cancers | 93 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Newly diagnosed | Maximal safe resection and molecular diagnosis with 1p/19q testing; observation is reasonable after gross total resection of a grade 2 tumour in a younger patient. | NCCN Guidelines: Central Nervous System Cancers | 71 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Grade 2, residual or recurrent, not needing radiotherapy | Vorasidenib (INDIGO) or continued observation. | NCCN Guidelines: Central Nervous System Cancers | 78 | |
| All comers | Recurrence | Re-resection, temozolomide or lomustine, re-irradiation; bevacizumab for symptoms. | 89 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.